In a post hoc analysis of the phase 3 VISION trial, investigators analyzed PSA decline and clinical and patient-reported outcomes in patients with mCRPC receiving 177Lu-PSMA-617.
8 raised its terrorism threat assessment to the second-highest level on a scale from 1 to 5 ... 11:36 AM UTC · Updated ago Europecategory Norway lowers national threat level to moderate from ...